Original Article: CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2 phase 3a trial) https: t.co qeoRH9mdiG Editorial: Expanding the Treat to Target Toolbox for Obesity and Diabetes Care https: t.co New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Sema Cag Blend 10mg Vial (>99% Purity) PeakForce Labs Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet